These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 617785)

  • 41. [Presence of inactive factor ix in variants of hemophilia, type B, and in carriers of hemophilia B].
    Elodi S
    Minerva Med; 1975 Jun; 66(42):2037-43. PubMed ID: 1138213
    [No Abstract]   [Full Text] [Related]  

  • 42. Somatic mosaicism and female-to-female transmission in a kindred with hemophilia B (factor IX deficiency).
    Taylor SA; Deugau KV; Lillicrap DP
    Proc Natl Acad Sci U S A; 1991 Jan; 88(1):39-42. PubMed ID: 1986380
    [TBL] [Abstract][Full Text] [Related]  

  • 43. An immunological investigation of hemophilia B with a tentative classification of the disease into five variants.
    Girolami A; Sticchi A; Burul A; Zanon RD
    Vox Sang; 1977; 32(4):230-8. PubMed ID: 857424
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Factor IX Chongqing: a new mutation in the calcium-binding domain of factor IX resulting in severe hemophilia B.
    Wang NS; Zhang M; Thompson AR; Chen SH
    Thromb Haemost; 1990 Feb; 63(1):24-6. PubMed ID: 2339358
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Immunological heterogeneity of haemophilia B: a multicentre study of 98 kindreds.
    Parekh VR; Mannucci PM; Ruggeri ZM
    Br J Haematol; 1978 Dec; 40(4):643-55. PubMed ID: 103564
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A Line 1 insertion in the Factor IX gene segregates with mild hemophilia B in dogs.
    Brooks MB; Gu W; Barnas JL; Ray J; Ray K
    Mamm Genome; 2003 Nov; 14(11):788-95. PubMed ID: 14722728
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Heterogeneity of the factor IX locus in nine hemophilia B inhibitor patients.
    Matthews RJ; Anson DS; Peake IR; Bloom AL
    J Clin Invest; 1987 Mar; 79(3):746-53. PubMed ID: 3029178
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Functional analysis of the factor IX epidermal growth factor-like domain mutation Ile66Thr associated with mild hemophilia B.
    Knobe KE; Persson KE; Sjörin E; Villoutreix BO; Ljung RC
    Pathophysiol Haemost Thromb; 2006; 35(5):370-5. PubMed ID: 17230038
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Antiserum against factor IX shortens the bovine thromboplastin coagulation time of human plasma.
    Orstavik KH; Laake K
    Thromb Res; 1978 Mar; 12(3):455-65. PubMed ID: 653636
    [No Abstract]   [Full Text] [Related]  

  • 50. Expression and characterization of a novel human recombinant factor IX molecule with enhanced in vitro and in vivo clotting activity.
    Perot E; Enjolras N; Le Quellec S; Indalecio A; Girard J; Negrier C; Dargaud Y
    Thromb Res; 2015 May; 135(5):1017-24. PubMed ID: 25795563
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Factor IX antigen by radioimmunoassay. Abnormal factor IX protein in patients on warfarin therapy and with hemophilia B.
    Thompson AR
    J Clin Invest; 1977 May; 59(5):900-10. PubMed ID: 856873
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Coagulation factor IX in normal and haemophilia B plasma.
    Somer JB; Castaldi PA
    Br J Haematol; 1970 Feb; 18(2):147-59. PubMed ID: 5439522
    [No Abstract]   [Full Text] [Related]  

  • 53. A simple method for analyzing factor IX activation in the patients with hemophilia B variants.
    Yoshioka A; Sakai T; Yamamoto K; Ohkubo Y; Fukui H
    Thromb Haemost; 1987 Aug; 58(2):705-8. PubMed ID: 3499681
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Hemophilia B Gene Therapy with a High-Specific-Activity Factor IX Variant.
    George LA; Sullivan SK; Giermasz A; Rasko JEJ; Samelson-Jones BJ; Ducore J; Cuker A; Sullivan LM; Majumdar S; Teitel J; McGuinn CE; Ragni MV; Luk AY; Hui D; Wright JF; Chen Y; Liu Y; Wachtel K; Winters A; Tiefenbacher S; Arruda VR; van der Loo JCM; Zelenaia O; Takefman D; Carr ME; Couto LB; Anguela XM; High KA
    N Engl J Med; 2017 Dec; 377(23):2215-2227. PubMed ID: 29211678
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Two distinct mutations cause severe hemophilia B in two unrelated canine pedigrees.
    Gu W; Brooks M; Catalfamo J; Ray J; Ray K
    Thromb Haemost; 1999 Oct; 82(4):1270-5. PubMed ID: 10544912
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Characterization of the original Christmas disease mutation (cysteine 206----serine): from clinical recognition to molecular pathogenesis.
    Taylor SA; Duffin J; Cameron C; Teitel J; Garvey B; Lillicrap DP
    Thromb Haemost; 1992 Jan; 67(1):63-5. PubMed ID: 1615485
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A method to estimate effects of amino acid substitutions in blood coagulation factor IX from hemophilia B patients.
    Furutani H
    Medinfo; 1995; 8 Pt 2():909. PubMed ID: 8591581
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A mutation in the 3' untranslated region of the factor IX gene in four families with hemophilia B.
    Vielhaber E; Jacobson DP; Ketterling RP; Liu JZ; Sommer SS
    Hum Mol Genet; 1993 Aug; 2(8):1309-10. PubMed ID: 8401514
    [No Abstract]   [Full Text] [Related]  

  • 59. Genetic variants of hemophilia B: detection by means of a specific PTC inhibitor.
    Roberts HR; Grizzle JE; McLester WD; Penick GD
    J Clin Invest; 1968 Feb; 47(2):360-5. PubMed ID: 12066779
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Variability of in vivo recovery of factor IX after infusion of monoclonal antibody purified factor IX concentrates in patients with hemophilia B. The Mononine Study Group.
    White GC; Shapiro AD; Kurczynski EM; Kim HC; Bergman GE
    Thromb Haemost; 1995 May; 73(5):779-84. PubMed ID: 7482403
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.